Lenalidomide Catalytic Reduction Solvent Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for preparing lenalidomide suffer from low yields and high solvent usage, making them hazardous and commercially unviable, with prior art methods resulting in low yields of both the final product and intermediate nitro compounds.
Innovation Solution
A process involving the catalytic reduction of 3-(1-oxo-4-nitro-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione using a solvent system comprising polar solvents such as acetonitrile and methanol, reducing solvent volume and improving yields to greater than 80% for lenalidomide and greater than 90% for the nitro intermediate, while maintaining chemical purity above 99.9% and 99.8% respectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional hydrogenation process is used with large solvent volume, then the reaction can proceed, but the process becomes hazardous and commercially unviable due to safety risks and poor economy
Solution Approach 1:
The patent changes the solvent system parameters by using a mixture of polar solvents (acetonitrile and methanol) instead of conventional large volumes of single solvents. This parameter change reduces solvent volume by up to 10-fold while maintaining reaction effectiveness, thereby improving safety and commercial viability without compromising reaction reliability
2Productivity
If conventional hydrogenation process is used, then the reaction can proceed, but the yield of final product is low (about 36%)
Solution Approach 1:
The patent optimizes reaction parameters by using a specific solvent system mixture of acetonitrile and methanol in controlled ratios. This parameter optimization increases the yield of lenalidomide from conventional 36% to greater than 80%, simultaneously improving reaction efficiency and reducing energy loss through better reaction control and reduced solvent volume
3Productivity
If conventional process is used for preparing nitro intermediate, then the reaction can proceed, but the yield is low (about 55%)
Solution Approach 1:
The patent changes the reaction parameters by using a solvent system of acetonitrile and methanol for the preparation of nitro intermediate. This parameter change improves the yield from conventional 55% to greater than 90%, reducing intermediate loss and improving overall process efficiency
4Ease of manufacture
If large amount of solvent is used in hydrogenation, then the reaction can proceed, but the process becomes economically unviable due to high solvent:substrate ratio
Solution Approach 1:
The patent optimizes the solvent:substrate ratio by using a mixture of polar solvents (acetonitrile and methanol) in controlled amounts. This parameter optimization reduces the solvent:substrate ratio by up to 10-fold compared to conventional processes, making the manufacturing process economically viable while maintaining ease of manufacture through improved reaction efficiency and reduced waste
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves a commercially viable and safer method for producing lenalidomide with high chemical purity, reducing solvent consumption by up to 10-fold and improving reaction efficiency, making it more economical and scalable.
Implementation Method 1
contacting the resulting mixture from step (i) with a catalyst
Implementation Method 2
contacting the mixture from step (ii) with hydrogen
Data Source
AI summary
The present invention relates to improved processes for preparing 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (I) (lenalidomide) and its intermediate 3-(1-oxo-4-nitro-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione. The present invention further relates to improved processes for preparing lenalidomide crystalline form A, use of said crystalline form A as an active pharmaceutical ingredient or as an intermediate in the preparation of further crystalline or amorphous forms of lenalidomide, compositions comprising lenalidomide crystalline form A and their use in the treatment of disease.